10,657 Shares in Cencora, Inc. (NYSE:COR) Bought by LGT Fund Management Co Ltd.

LGT Fund Management Co Ltd. bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,657 shares of the company's stock, valued at approximately $2,394,000.

Other hedge funds also recently modified their holdings of the company. Venturi Wealth Management LLC raised its holdings in shares of Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock worth $1,001,000 after buying an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC boosted its position in shares of Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after purchasing an additional 46 shares during the last quarter. Shepherd Financial Partners LLC lifted its holdings in Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after acquiring an additional 46 shares in the last quarter. WASHINGTON TRUST Co lifted its holdings in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares in the last quarter. Finally, JFS Wealth Advisors LLC raised its stake in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,648 shares of company stock valued at $2,862,342 over the last 90 days. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

NYSE:COR traded down $1.88 during trading hours on Wednesday, hitting $251.40. 1,520,486 shares of the company were exchanged, compared to its average volume of 1,505,621. The company's 50 day moving average price is $243.25 and its 200-day moving average price is $238.18. The stock has a market capitalization of $48.75 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 1.31 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent research reports. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Robert W. Baird increased their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. StockNews.com cut shares of Cencora from a "buy" rating to a "hold" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.